Institutional portfolio tracker

Viking Global Portfolio & AI Predictions

Explore Viking Global's latest validated 13F portfolio and Hallucination Yield AI forecasts for covered positions.

Form 13F reports holdings as of 2026-03-31 and was filed on 2026-05-15. It is delayed, can omit confidential positions, and is not the manager's current portfolio or fund NAV. Options show reported underlying value—not premium, net exposure, or investment intent.

Disclosed long book

$34.90 billion

Long positions

77

Calls / puts

0 / 0

Top 5 concentration

21.0%

Longs with AI data

9 / 77

Average AI 1Y

+18.0%

Official SEC filing ↗ Exact filing event Permanent quarter page JSON Download CSV

Monitored between quarterly reports

Beneficial-ownership disclosures

Schedules 13D and 13G can reveal a significant ownership event after a quarter closes. They are shown as a separate event timeline and never folded back into the 2026-03-31 Form 13F portfolio.

BridgeBio Pharma, Inc.

SCHEDULE 13D/APost-quarter event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of July 9, 2026: 9,792,219 shares or share-equivalents representing 5% of the reported class. It was filed on July 10, 2026.

Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Common Stock, par value $0.001 per share (the "Common Stock"), of BridgeBio Pharma, Inc. (the "Issuer"). The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101. All share percentage calculations in this Amendment No. 12 to the Schedule 13D are based on 196,036,786 shares of Common Stock of the Issuer outstanding as of May 31, 2026, as reported in exhibit 10.1 to the Issuer's current report on Form 8-K filed with the

Official SEC disclosure ↗

STANDARD BIOTOOLS INC.

SCHEDULE 13DPost-quarter event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 6, 2026: 58,651,170 shares or share-equivalents representing 15% of the reported class. It was filed on June 12, 2026.

All share percentage calculations in this Schedule 13D are based on 390,368,119 shares of Common Stock outstanding as of May 4, 2026, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2026.

Official SEC disclosure ↗

Artiva Biotherapeutics, Inc.

SCHEDULE 13GPost-quarter event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of May 11, 2026: 2,604,166 shares or share-equivalents representing 5.4% of the reported class. It was filed on May 18, 2026.

See Item 4

Official SEC disclosure ↗

Inhibrx Biosciences, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 1,461,633 shares or share-equivalents representing 9.99% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Oruka Therapeutics, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 2,666,690 shares or share-equivalents representing 5.3% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

PepGen Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 3,482,434 shares or share-equivalents representing 5.03% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Veradermics, Inc

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 1,690,555 shares or share-equivalents representing 4.5% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Pharvaris N.V.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 3,653,310 shares or share-equivalents representing 5.6% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Adaptive Biotechnologies Corp

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 29,993,708 shares or share-equivalents representing 18.8% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Sionna Therapeutics, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 3,195,181 shares or share-equivalents representing 7.1% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Oric Pharmaceuticals, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 8,264,607 shares or share-equivalents representing 7.8% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

TIC Solutions, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 35,824,562 shares or share-equivalents representing 16.2% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

STANDARD BIOTOOLS INC.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 58,651,170 shares or share-equivalents representing 15% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Fortive Corp

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 22,479,388 shares or share-equivalents representing 7.1% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Rallybio Corporation

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 528,954 shares or share-equivalents representing 9.99% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Chewy, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 0 shares or share-equivalents representing 0% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Ginkgo Bioworks Holdings, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 3,577,128 shares or share-equivalents representing 7.1% of the reported class. It was filed on May 15, 2026.

See Item 4

Official SEC disclosure ↗

Altimmune, Inc.

SCHEDULE 13GPost-quarter event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of April 24, 2026: 13,400,000 shares or share-equivalents representing 6.7% of the reported class. It was filed on May 1, 2026.

See Item 4

Official SEC disclosure ↗

LENNOX INTERNATIONAL INC

SCHEDULE 13GPost-quarter event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of April 15, 2026: 1,815,350 shares or share-equivalents representing 5.2% of the reported class. It was filed on April 22, 2026.

See Item 4

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 11,842,434 shares or share-equivalents representing 6.1% of the reported class. It was filed on April 2, 2026.

All share percentage calculations in this Amendment No. 11 to the Schedule 13D are based on 193,862,871 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of February 12, 2026, as reported in the Issuer's annual report on Form 10-K filed with the Securities and Exchange Commission (the "Commission") on February 24, 2026.

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of February 12, 2026: 13,026,367 shares or share-equivalents representing 6.8% of the reported class. It was filed on February 17, 2026.

All share percentage calculations in this Amendment No. 10 to the Schedule 13D are based on the difference between (i) 192,708,813 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of October 21, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on October 29, 2025, and (ii) 1,081,825 shares of Common Stock that the Issuer repurchased on January 21, 2026, as reported in the Issuer's current report on Form 8-K filed with the Commission on January 21, 2026.

Official SEC disclosure ↗

Rallybio Corporation

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 4,222,969 shares or share-equivalents representing 9.99% of the reported class. It was filed on February 17, 2026.

See Item 4

Official SEC disclosure ↗

Inhibrx Biosciences, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 1,454,608 shares or share-equivalents representing 9.99% of the reported class. It was filed on February 17, 2026.

See Item 4

Official SEC disclosure ↗

Primo Brands Corp

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 0 shares or share-equivalents representing 0% of the reported class. It was filed on February 17, 2026.

See Item 4

Official SEC disclosure ↗

SAIA INC

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 1,088,582 shares or share-equivalents representing 4.1% of the reported class. It was filed on February 17, 2026.

See Item 4

Official SEC disclosure ↗

NewAmsterdam Pharma Co N.V.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 4,203,567 shares or share-equivalents representing 3.7% of the reported class. It was filed on February 17, 2026.

See Item 4

Official SEC disclosure ↗

Veradermics, Inc

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of February 5, 2026: 2,151,493 shares or share-equivalents representing 5.8% of the reported class. It was filed on February 12, 2026.

See Item 4

Official SEC disclosure ↗

REGAL REXNORD CORP

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of January 6, 2026: 3,301,545 shares or share-equivalents representing 4.97% of the reported class. It was filed on January 13, 2026.

See Item 4

Official SEC disclosure ↗

Chewy, Inc.

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 18, 2025: 13,536,645 shares or share-equivalents representing 5.7% of the reported class. It was filed on December 30, 2025.

See Item 4

Official SEC disclosure ↗

Trevi Therapeutics, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 5,128,875 shares or share-equivalents representing 4.2% of the reported class. It was filed on November 14, 2025.

See Item 4

Official SEC disclosure ↗

Roivant Sciences Ltd.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 23,594,831 shares or share-equivalents representing 3.4% of the reported class. It was filed on November 14, 2025.

See Item 4

Official SEC disclosure ↗

REGAL REXNORD CORP

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 3,123,262 shares or share-equivalents representing 4.7% of the reported class. It was filed on November 14, 2025.

See Item 4

Official SEC disclosure ↗

BIOMARIN PHARMACEUTICAL INC

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 8,322,179 shares or share-equivalents representing 4.3% of the reported class. It was filed on November 14, 2025.

See Item 4

Official SEC disclosure ↗

Fortive Corp

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 20,483,680 shares or share-equivalents representing 6.4% of the reported class. It was filed on November 14, 2025.

See Item 4

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of November 14, 2025: 15,893,934 shares or share-equivalents representing 8.2% of the reported class. It was filed on November 14, 2025.

All share percentage calculations in this Amendment No. 9 to the Schedule 13D are based on 192,708,813 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of October 21, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on October 29, 2025.

Official SEC disclosure ↗

PepGen Inc.

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 26, 2025: 3,482,434 shares or share-equivalents representing 5.1% of the reported class. It was filed on October 3, 2025.

See Item 4

Official SEC disclosure ↗

Oruka Therapeutics, Inc.

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 17, 2025: 2,666,690 shares or share-equivalents representing 5.5% of the reported class. It was filed on September 24, 2025.

See Item 4

Official SEC disclosure ↗

SAIA INC

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 3, 2025: 1,337,356 shares or share-equivalents representing 5.02% of the reported class. It was filed on September 10, 2025.

See Item 4

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of August 14, 2025: 17,780,183 shares or share-equivalents representing 9.3% of the reported class. It was filed on August 14, 2025.

All share percentage calculations in this Amendment No. 8 to the Schedule 13D are based on 191,168,504 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of July 29, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on August 5, 2025.

Official SEC disclosure ↗

Trevi Therapeutics, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 7,505,694 shares or share-equivalents representing 5.9% of the reported class. It was filed on August 14, 2025.

See Item 4

Official SEC disclosure ↗

APi Group Corp

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 11,537,518 shares or share-equivalents representing 2.8% of the reported class. It was filed on August 14, 2025.

See Item 4

Official SEC disclosure ↗

Oric Pharmaceuticals, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 8,729,345 shares or share-equivalents representing 9.99% of the reported class. It was filed on August 14, 2025.

See Item 4

Official SEC disclosure ↗

REGAL REXNORD CORP

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 3,430,128 shares or share-equivalents representing 5.2% of the reported class. It was filed on August 14, 2025.

See Item 4

Official SEC disclosure ↗

BIOMARIN PHARMACEUTICAL INC

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 12,288,611 shares or share-equivalents representing 6.4% of the reported class. It was filed on August 14, 2025.

See Item 4

Official SEC disclosure ↗

Roivant Sciences Ltd.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 34,237,779 shares or share-equivalents representing 5.02% of the reported class. It was filed on August 14, 2025.

See Item 4

Official SEC disclosure ↗

Fortive Corp

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of July 17, 2025: 17,049,178 shares or share-equivalents representing 5.02% of the reported class. It was filed on July 24, 2025.

See Item 4

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 27, 2025: 18,602,920 shares or share-equivalents representing 9.8% of the reported class. It was filed on July 1, 2025.

All share percentage calculations in this Amendment No. 7 to the Schedule 13D are based on 189,880,720 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of April 22, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on April 29, 2025.

Official SEC disclosure ↗

Primo Brands Corp

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 11, 2025: 19,602,116 shares or share-equivalents representing 5.3% of the reported class. It was filed on June 18, 2025.

See Item 4

Official SEC disclosure ↗

Roivant Sciences Ltd.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2025: 46,013,752 shares or share-equivalents representing 6.4% of the reported class. It was filed on May 15, 2025.

See Item 4

Official SEC disclosure ↗

Oric Pharmaceuticals, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2025: 6,572,700 shares or share-equivalents representing 9.2% of the reported class. It was filed on May 15, 2025.

See Item 4

Official SEC disclosure ↗

Trevi Therapeutics, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2025: 9,190,486 shares or share-equivalents representing 8.7% of the reported class. It was filed on May 15, 2025.

See Item 4

Official SEC disclosure ↗

ACUREN CORP

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2025: 34,360,000 shares or share-equivalents representing 28.3% of the reported class. It was filed on May 15, 2025.

See Item 4

Official SEC disclosure ↗

REGAL REXNORD CORP

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of April 11, 2025: 3,546,112 shares or share-equivalents representing 5.3% of the reported class. It was filed on April 18, 2025.

See Item 4

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of January 31, 2025: 22,055,375 shares or share-equivalents representing 11.7% of the reported class. It was filed on March 12, 2025.

All share percentage calculations in this Amendment No. 6 to the Schedule 13D are based on 188,989,802 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of November 5, 2024, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on November 12, 2024.

Official SEC disclosure ↗

Cazoo Group Ltd

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of February 1, 2024: 2,142,728 shares or share-equivalents representing 43.8% of the reported class. It was filed on March 12, 2025.

All share percentage calculations in this Amendment No. 13 to the Schedule 13D are based on 4,891,002 Ordinary Shares (as defined herein) expected to be outstanding after giving effect to each of the December 2023 Reverse Stock Split (as defined in Amendment No. 12) and the issuance of the New Shares (as defined in Amendment No. 12), as reported in the Issuer's current report on Form 6-K filed with the U.S. Securities and Exchange Commission (the "Commission") on December 7, 2023.

Official SEC disclosure ↗

Sionna Therapeutics, Inc.

SCHEDULE 13GSeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of February 10, 2025: 2,952,754 shares or share-equivalents representing 6.7% of the reported class. It was filed on February 14, 2025.

See Item 4

Official SEC disclosure ↗

Longboard Pharmaceuticals, Inc.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2024: 0 shares or share-equivalents representing 0% of the reported class. It was filed on February 14, 2025.

See Item 4

Official SEC disclosure ↗

NewAmsterdam Pharma Co N.V.

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2024: 6,978,534 shares or share-equivalents representing 6.5% of the reported class. It was filed on February 14, 2025.

See Item 4

Official SEC disclosure ↗

APi Group Corp

SCHEDULE 13G/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2024: 21,537,518 shares or share-equivalents representing 7.8% of the reported class. It was filed on February 14, 2025.

See Item 4

Official SEC disclosure ↗

BridgeBio Pharma, Inc.

SCHEDULE 13D/ASeparate ownership event

The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of January 31, 2025: 22,055,375 shares or share-equivalents representing 11.7% of the reported class. It was filed on January 31, 2025.

All share percentage calculations in this Amendment No. 5 to the Schedule 13D are based on 188,989,802 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of November 5, 2024, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on November 12, 2024.

Official SEC disclosure ↗
PositionKindSharesValueLong weightQuarter changeAI at filing · 1YAI now

V

VISA INC · COM CL A · 92826C839

 LONG 6,328,185 $1.91 billion 5.5% INCREASED —

1Y —

5Y —

TSM

TAIWAN SEMICONDUCTOR MANUFAC · SPONSORED ADS · 874039100

 LONG 4,465,127 $1.51 billion 4.3% REDUCED —

1Y +23.6%

5Y +131.0% · 5 models

SCHWAB CHARLES CORP

SCHWAB CHARLES CORP · COM · 808513105

 LONG 14,664,954 $1.38 billion 3.9% INCREASED —

1Y —

5Y —

DISNEY WALT CO

DISNEY WALT CO · COM · 254687106

 LONG 13,298,462 $1.28 billion 3.7% INCREASED —

1Y —

5Y —

FORTIVE CORP

FORTIVE CORP · COM · 34959J108

 LONG 22,479,388 $1.24 billion 3.6% INCREASED —

1Y —

5Y —

AIR PRODUCTS AND CHEMICALS I

AIR PRODUCTS AND CHEMICALS I · COM · 009158106

 LONG 4,104,095 $1.19 billion 3.4% REDUCED —

1Y —

5Y —

MCDONALDS CORP

MCDONALDS CORP · COM · 580135101

 LONG 3,625,029 $1.13 billion 3.2% INCREASED —

1Y —

5Y —

SHERWIN WILLIAMS CO

SHERWIN WILLIAMS CO · COM · 824348106

 LONG 3,112,767 $997.8 million 2.9% REDUCED —

1Y —

5Y —

TSLA

TESLA INC · COM · 88160R101

 LONG 2,493,561 $927.0 million 2.7% INCREASED —

1Y +6.2%

5Y +98.3% · 6 models

APPLE INC

APPLE INC · COM · 037833100

 LONG 3,593,057 $911.9 million 2.6% NEWLY REPORTED —

1Y —

5Y —

BRIDGEBIO PHARMA INC

BRIDGEBIO PHARMA INC · COM · 10806X102

 LONG 11,842,434 $879.4 million 2.5% REDUCED —

1Y —

5Y —

CVNA

CARVANA CO · CL A · 146869102

 LONG 2,780,035 $874.0 million 2.5% INCREASED —

1Y —

5Y —

MSFT

MICROSOFT CORP · COM · 594918104

 LONG 2,309,446 $854.9 million 2.4% REDUCED —

1Y +14.8%

5Y +90.8% · 6 models

THERMO FISHER SCIENTIFIC INC

THERMO FISHER SCIENTIFIC INC · COM · 883556102

 LONG 1,668,025 $819.9 million 2.3% INCREASED —

1Y —

5Y —

JPMORGAN CHASE & CO

JPMORGAN CHASE & CO · COM · 46625H100

 LONG 2,704,018 $795.4 million 2.3% INCREASED —

1Y —

5Y —

CSX CORP

CSX CORP · COM · 126408103

 LONG 18,678,052 $766.7 million 2.2% INCREASED —

1Y —

5Y —

INTERCONTINENTAL EXCHANGE IN

INTERCONTINENTAL EXCHANGE IN · COM · 45866F104

 LONG 4,836,896 $760.7 million 2.2% INCREASED —

1Y —

5Y —

LENNOX INTL INC

LENNOX INTL INC · COM · 526107107

 LONG 1,572,419 $729.8 million 2.1% INCREASED —

1Y —

5Y —

GOOGL

ALPHABET INC · CAP STK CL A · 02079K305

 LONG 2,395,865 $689.0 million 2.0% REDUCED —

1Y +15.8%

5Y +98.3% · 6 models

FEDEX CORP

FEDEX CORP · COM · 31428X106

 LONG 1,932,165 $688.2 million 2.0% NEWLY REPORTED —

1Y —

5Y —

GENERAL MTRS CO

GENERAL MTRS CO · COM · 37045V100

 LONG 9,176,943 $683.7 million 2.0% INCREASED —

1Y —

5Y —

BOEING CO

BOEING CO · COM · 097023105

 LONG 3,196,041 $636.1 million 1.8% REDUCED —

1Y —

5Y —

PNC FINL SVCS GROUP INC

PNC FINL SVCS GROUP INC · COM · 693475105

 LONG 3,027,092 $629.9 million 1.8% REDUCED —

1Y —

5Y —

T-MOBILE US INC

T-MOBILE US INC · COM · 872590104

 LONG 2,967,374 $623.2 million 1.8% REDUCED —

1Y —

5Y —

META

META PLATFORMS INC · CL A · 30303M102

 LONG 1,062,575 $607.9 million 1.7% NEWLY REPORTED —

1Y +18.8%

5Y +116.7% · 6 models

REGAL REXNORD CORPORATION

REGAL REXNORD CORPORATION · COM · 758750103

 LONG 3,142,851 $588.5 million 1.7% REDUCED —

1Y —

5Y —

MID-AMER APT CMNTYS INC

MID-AMER APT CMNTYS INC · COM · 59522J103

 LONG 4,798,404 $586.0 million 1.7% INCREASED —

1Y —

5Y —

JOHNSON CONTROLS INTERNATION

JOHNSON CONTROLS INTERNATION · SHS · G51502105

 LONG 4,419,923 $578.8 million 1.7% REDUCED —

1Y —

5Y —

MEDLINE INC

MEDLINE INC · COM CL A · 58507V107

 LONG 11,433,992 $508.8 million 1.5% INCREASED —

1Y —

5Y —

HCA HEALTHCARE INC

HCA HEALTHCARE INC · COM · 40412C101

 LONG 1,075,133 $508.8 million 1.5% INCREASED —

1Y —

5Y —

ATI INC

ATI INC · COM · 01741R102

 LONG 3,332,843 $484.8 million 1.4% NEWLY REPORTED —

1Y —

5Y —

CELESTICA INC

CELESTICA INC · COM · 15101Q207

 LONG 1,654,989 $466.2 million 1.3% REDUCED —

1Y —

5Y —

CAMDEN PPTY TR

CAMDEN PPTY TR · SH BEN INT · 133131102

 LONG 4,715,394 $460.5 million — REDUCED —

1Y —

5Y —

CHUBB LTD SWITZ

CHUBB LTD SWITZ · COM · H1467J104

 LONG 1,295,011 $422.1 million 1.2% INCREASED —

1Y —

5Y —

ADAPTIVE BIOTECHNOLOGIES COR

ADAPTIVE BIOTECHNOLOGIES COR · COM · 00650F109

 LONG 29,993,708 $416.3 million 1.2% UNCHANGED —

1Y —

5Y —

BIOMARIN PHARMACEUTICAL INC

BIOMARIN PHARMACEUTICAL INC · COM · 09061G101

 LONG 7,062,077 $398.9 million 1.1% INCREASED —

1Y —

5Y —

SEA LTD

SEA LTD · SPONSORD ADS · 81141R100

 LONG 4,737,196 $392.3 million — INCREASED —

1Y —

5Y —

WATERS CORP

WATERS CORP · COM · 941848103

 LONG 1,256,462 $374.2 million 1.1% NEWLY REPORTED —

1Y —

5Y —

CARNIVAL CORP

CARNIVAL CORP · COMMON STOCK · 143658300

 LONG 13,721,348 $355.1 million 1.0% NEWLY REPORTED —

1Y —

5Y —

AON PLC

AON PLC · SHS CL A · G0403H108

 LONG 1,087,114 $350.9 million 1.0% INCREASED —

1Y —

5Y —

HASBRO INC

HASBRO INC · COM · 418056107

 LONG 3,738,902 $350.0 million 1.0% NEWLY REPORTED —

1Y —

5Y —

RDDT

REDDIT INC · CL A · 75734B100

 LONG 2,551,617 $343.6 million 1.0% NEWLY REPORTED —

1Y +22.6%

5Y +138.0% · 5 models

PROGRESSIVE CORP

PROGRESSIVE CORP · COM · 743315103

 LONG 1,616,559 $320.5 million 0.9% INCREASED —

1Y —

5Y —

AMERICAN INTL GROUP INC

AMERICAN INTL GROUP INC · COM NEW · 026874784

 LONG 4,221,223 $317.6 million 0.9% NEWLY REPORTED —

1Y —

5Y —

CAPITAL ONE FINL CORP

CAPITAL ONE FINL CORP · COM · 14040H105

 LONG 1,612,374 $294.1 million 0.8% REDUCED —

1Y —

5Y —

DKS

DICKS SPORTING GOODS INC · COM · 253393102

 LONG 1,264,170 $250.7 million 0.7% REDUCED —

1Y —

5Y —

AMZN

AMAZON COM INC · COM · 023135106

 LONG 1,195,428 $249.0 million 0.7% REDUCED —

1Y +19.2%

5Y +115.8% · 6 models

AMER SPORTS INC

AMER SPORTS INC · COM SHS · G0260P102

 LONG 7,270,476 $239.3 million 0.7% INCREASED —

1Y —

5Y —

API GROUP CORP

API GROUP CORP · COM STK · 00187Y100

 LONG 5,837,000 $236.5 million 0.7% REDUCED —

1Y —

5Y —

TIC SOLUTIONS INC

TIC SOLUTIONS INC · COM · 00510N102

 LONG 35,824,562 $235.7 million 0.7% INCREASED —

1Y —

5Y —

CBOE GLOBAL MKTS INC

CBOE GLOBAL MKTS INC · COM · 12503M108

 LONG 688,417 $193.5 million 0.6% NEWLY REPORTED —

1Y —

5Y —

ROIVANT SCIENCES LTD

ROIVANT SCIENCES LTD · SHS · G76279101

 LONG 6,652,448 $184.3 million 0.5% INCREASED —

1Y —

5Y —

HOME DEPOT INC

HOME DEPOT INC · COM · 437076102

 LONG 504,257 $165.8 million 0.5% NEWLY REPORTED —

1Y —

5Y —

GALLAGHER ARTHUR J & CO

GALLAGHER ARTHUR J & CO · COM · 363576109

 LONG 727,441 $157.5 million 0.5% REDUCED —

1Y —

5Y —

LULULEMON ATHLETICA INC

LULULEMON ATHLETICA INC · COM · 550021109

 LONG 980,568 $150.1 million 0.4% NEWLY REPORTED —

1Y —

5Y —

NEWAMSTERDAM PHARMA COMPANY

NEWAMSTERDAM PHARMA COMPANY · ORDINARY SHARES · N62509109

 LONG 4,203,567 $134.6 million 0.4% UNCHANGED —

1Y —

5Y —

ORUKA THERAPEUTICS INC

ORUKA THERAPEUTICS INC · COM · 687604108

 LONG 2,666,690 $130.8 million 0.4% UNCHANGED —

1Y —

5Y —

SIONNA THERAPEUTICS INC

SIONNA THERAPEUTICS INC · COM · 829401108

 LONG 3,195,181 $128.1 million 0.4% UNCHANGED —

1Y —

5Y —

STELLANTIS N.V

STELLANTIS N.V · SHS · N82405106

 LONG 15,980,268 $111.9 million 0.3% REDUCED —

1Y —

5Y —

CRWV

COREWEAVE INC · COM CL A · 21873S108

 LONG 1,397,438 $108.3 million 0.3% NEWLY REPORTED —

1Y +22.6%

5Y +121.0% · 5 models

VERADERMICS INC

VERADERMICS INC · COMMON STOCK · 922967104

 LONG 1,690,555 $106.8 million 0.3% NEWLY REPORTED —

1Y —

5Y —

WEST PHARMACEUTICAL SVSC INC

WEST PHARMACEUTICAL SVSC INC · COM · 955306105

 LONG 416,948 $104.5 million 0.3% INCREASED —

1Y —

5Y —

PHARVARIS N V

PHARVARIS N V · COM · N69605108

 LONG 3,653,310 $103.2 million 0.3% UNCHANGED —

1Y —

5Y —

INHIBRX BIOSCIENCES INC

INHIBRX BIOSCIENCES INC · COM · 45720N103

 LONG 1,437,705 $96.7 million 0.3% UNCHANGED —

1Y —

5Y —

INTERACTIVE BROKERS GROUP IN

INTERACTIVE BROKERS GROUP IN · COM CL A · 45841N107

 LONG 1,394,329 $93.5 million 0.3% NEWLY REPORTED —

1Y —

5Y —

RALLIANT CORP

RALLIANT CORP · COM · 750940108

 LONG 2,134,899 $88.8 million 0.3% REDUCED —

1Y —

5Y —

EDWARDS LIFESCIENCES CORP

EDWARDS LIFESCIENCES CORP · COM · 28176E108

 LONG 1,097,578 $87.9 million 0.3% NEWLY REPORTED —

1Y —

5Y —

ORIC PHARMACEUTICALS INC

ORIC PHARMACEUTICALS INC · COM · 68622P109

 LONG 5,824,533 $73.8 million 0.2% REDUCED —

1Y —

5Y —

DAMORA THERAPEUTICS INC

DAMORA THERAPEUTICS INC · COM NEW · 36322Q206

 LONG 2,311,082 $59.9 million 0.2% NEWLY REPORTED —

1Y —

5Y —

TWLO

TWILIO INC · CL A · 90138F102

 LONG 450,770 $56.7 million 0.2% NEWLY REPORTED —

1Y +18.2%

5Y +94.0% · 5 models

STANDARD BIOTOOLS INC

STANDARD BIOTOOLS INC · COM · 34385P108

 LONG 58,651,170 $53.9 million 0.2% UNCHANGED —

1Y —

5Y —

TREVI THERAPEUTICS INC

TREVI THERAPEUTICS INC · COM · 89532M101

 LONG 3,198,644 $38.2 million 0.1% UNCHANGED —

1Y —

5Y —

GINKGO BIOWORKS HOLDINGS INC

GINKGO BIOWORKS HOLDINGS INC · CL A NEW · 37611X209

 LONG 3,577,128 $21.9 million 0.1% UNCHANGED —

1Y —

5Y —

EQPT

EQUIPMENTSHARE COM INC · COM CL A · 29445S100

 LONG 1,000,000 $20.4 million 0.1% NEWLY REPORTED —

1Y —

5Y —

FORGENT POWER SOLUTIONS INC

FORGENT POWER SOLUTIONS INC · COM SHS CL A · 34631F102

 LONG 650,000 $19.0 million 0.1% NEWLY REPORTED —

1Y —

5Y —

PEPGEN INC

PEPGEN INC · COM · 713317105

 LONG 3,482,434 $6.2 million 0.0% UNCHANGED —

1Y —

5Y —

RALLYBIO CORP

RALLYBIO CORP · COM · 75120L209

 LONG 524,347 $4.7 million 0.0% NEWLY REPORTED —

1Y —

5Y —
AI outlook values are averages across the latest successful run per covered model at the labeled cutoff. “No longer reported” does not necessarily mean sold; thresholds, confidential treatment, corporate actions, or instrument changes may explain an omission. Reviewed API mapping covers 0.0% of disclosed long-book value; exact editorial CUSIP mappings may add current-only AI coverage on this public page. Research use only. No warranty and not investment advice.

Filing history

Get filing alerts →

Every filing event remains separate, including notices and amendments. Open a holdings date for the canonical portfolio through its latest filing, or an accession for the exact source event.

Holdings dateFiledFormProcessingAccession
2026-03-31 2026-05-15 13F-HR VALIDATED 0001103804-26-000004
2025-12-31 2026-02-17 13F-HR VALIDATED 0001103804-26-000002
2025-09-30 2025-11-14 13F-HR VALIDATED 0001103804-25-000010
2025-06-30 2025-08-14 13F-HR VALIDATED 0001103804-25-000007
2025-03-31 2025-05-15 13F-HR VALIDATED 0001103804-25-000004
2024-12-31 2025-02-14 13F-HR VALIDATED 0001103804-25-000002
2024-09-30 2024-11-14 13F-HR VALIDATED 0001103804-24-000006
2024-06-30 2024-08-14 13F-HR VALIDATED 0000905148-24-002226
2024-03-31 2024-05-15 13F-HR VALIDATED 0001103804-24-000004
2023-12-31 2024-02-14 13F-HR VALIDATED 0001103804-24-000002
2023-09-30 2023-11-14 13F-HR VALIDATED 0001103804-23-000009
2023-06-30 2023-08-14 13F-HR VALIDATED 0001103804-23-000006
2023-03-31 2023-05-15 13F-HR VALIDATED 0001103804-23-000004
2022-12-31 2023-02-14 13F-HR VALIDATED 0001103804-23-000002
2022-09-30 2022-11-14 13F-HR VALIDATED 0001103804-22-000006
2022-06-30 2022-08-15 13F-HR VALIDATED 0001103804-22-000004
2021-12-31 2022-05-16 13F-HR/A · restatement VALIDATED 0001567619-22-010954
2021-09-30 2022-05-16 13F-HR/A · restatement VALIDATED 0001567619-22-010950
2022-03-31 2022-05-16 13F-HR VALIDATED 0001103804-22-000003
2021-12-31 2022-02-14 13F-HR VALIDATED 0001103804-22-000002
2021-09-30 2021-11-15 13F-HR VALIDATED 0001103804-21-000009
2021-06-30 2021-08-16 13F-HR VALIDATED 0001103804-21-000006
2021-03-31 2021-05-17 13F-HR VALIDATED 0001103804-21-000004
2020-12-31 2021-02-16 13F-HR VALIDATED 0001103804-21-000003
2020-09-30 2020-11-16 13F-HR VALIDATED 0001103804-20-000009
2020-06-30 2020-08-07 13F-HR VALIDATED 0001103804-20-000007
2020-03-31 2020-05-13 13F-HR VALIDATED 0001103804-20-000005
2019-12-31 2020-02-13 13F-HR VALIDATED 0001103804-20-000003
2019-09-30 2019-11-13 13F-HR VALIDATED 0001103804-19-000014
2019-06-30 2019-08-14 13F-HR VALIDATED 0001103804-19-000011
2019-03-31 2019-05-15 13F-HR VALIDATED 0001103804-19-000006
2018-12-31 2019-02-14 13F-HR VALIDATED 0001103804-19-000002
2018-09-30 2018-11-14 13F-HR VALIDATED 0001103804-18-000045
2018-06-30 2018-08-14 13F-HR VALIDATED 0001103804-18-000039
2018-03-31 2018-05-15 13F-HR VALIDATED 0001103804-18-000031
2017-12-31 2018-02-14 13F-HR VALIDATED 0001103804-18-000004
2017-09-30 2017-11-14 13F-HR VALIDATED 0001103804-17-000061
2017-06-30 2017-08-14 13F-HR VALIDATED 0001103804-17-000049
2017-03-31 2017-05-15 13F-HR VALIDATED 0001103804-17-000040
2016-12-31 2017-02-14 13F-HR VALIDATED 0001103804-17-000034
2016-09-30 2016-11-14 13F-HR VALIDATED 0001103804-16-000126
2016-06-30 2016-08-15 13F-HR VALIDATED 0001103804-16-000123
2016-03-31 2016-05-16 13F-HR VALIDATED 0001103804-16-000116
2015-12-31 2016-02-16 13F-HR VALIDATED 0001103804-16-000077
2015-09-30 2015-11-16 13F-HR VALIDATED 0001103804-15-000061
2015-06-30 2015-08-14 13F-HR VALIDATED 0001103804-15-000048
2015-03-31 2015-05-15 13F-HR VALIDATED 0001103804-15-000034
2014-12-31 2015-02-17 13F-HR VALIDATED 0001103804-15-000015
2014-09-30 2014-11-14 13F-HR VALIDATED 0001103804-14-000044
2014-06-30 2014-08-14 13F-HR VALIDATED 0001103804-14-000036
2014-03-31 2014-05-15 13F-HR VALIDATED 0001103804-14-000027
2013-12-31 2014-02-14 13F-HR VALIDATED 0000902664-14-001132
2013-09-30 2013-11-14 13F-HR VALIDATED 0000902664-13-003741
2013-06-30 2013-08-14 13F-HR VALIDATED 0000902664-13-002950
2013-03-31 2013-05-14 13F-HR VALIDATED 0001103804-13-000022
2012-12-31 2013-02-14 13F-HR VALIDATED 0001103804-13-000004
2012-09-30 2012-11-14 13F-HR VALIDATED 0001103804-12-000035
2012-06-30 2012-08-14 13F-HR VALIDATED 0001103804-12-000030
2012-03-31 2012-05-15 13F-HR VALIDATED 0001103804-12-000027
2011-12-31 2012-02-14 13F-HR VALIDATED 0001103804-12-000022
2011-09-30 2011-11-14 13F-HR VALIDATED 0001103804-11-000041
2011-06-30 2011-08-15 13F-HR VALIDATED 0001103804-11-000037
2011-03-31 2011-05-16 13F-HR VALIDATED 0001103804-11-000033
2010-12-31 2011-02-11 13F-HR QUARANTINED 0001103804-11-000023
2010-09-30 2010-11-15 13F-HR QUARANTINED 0000902664-10-003592
2010-06-30 2010-08-16 13F-HR QUARANTINED 0001103804-10-000011
2010-03-31 2010-05-17 13F-HR QUARANTINED 0001103804-10-000005
2009-12-31 2010-02-16 13F-HR QUARANTINED 0001103804-10-000003
2009-09-30 2009-11-16 13F-HR QUARANTINED 0001103804-09-000014
2009-06-30 2009-08-17 13F-HR/A · add new holdings VALIDATED 0001103804-09-000011
2009-06-30 2009-08-14 13F-HR VALIDATED 0001103804-09-000008
2009-03-31 2009-05-15 13F-HR VALIDATED 0001103804-09-000005
2008-12-31 2009-02-17 13F-HR VALIDATED 0001103804-09-000002
2008-09-30 2008-11-14 13F-HR QUARANTINED 0001103804-08-000016
2008-06-30 2008-08-14 13F-HR VALIDATED 0001103804-08-000013
2008-03-31 2008-05-15 13F-HR QUARANTINED 0001103804-08-000010
2007-12-31 2008-02-19 13F-HR/A · restatement VALIDATED 0001103804-08-000007
2007-12-31 2008-02-14 13F-HR VALIDATED 0001103804-08-000006
2007-09-30 2007-11-14 13F-HR VALIDATED 0001103804-07-000013
2007-06-30 2007-08-14 13F-HR VALIDATED 0001103804-07-000010
2007-03-31 2007-05-15 13F-HR VALIDATED 0001103804-07-000007
2006-12-31 2007-02-14 13F-HR VALIDATED 0001103804-07-000002
2006-09-30 2006-11-14 13F-HR QUARANTINED 0001103804-06-000018
2006-06-30 2006-08-14 13F-HR VALIDATED 0001103804-06-000016
2006-03-31 2006-05-15 13F-HR VALIDATED 0001103804-06-000013
2005-12-31 2006-02-14 13F-HR VALIDATED 0001103804-06-000005
2005-09-30 2005-11-14 13F-HR VALIDATED 0001103804-05-000019
2005-06-30 2005-08-15 13F-HR VALIDATED 0001103804-05-000013
2005-03-31 2005-05-16 13F-HR VALIDATED 0001103804-05-000011
2004-12-31 2005-02-15 13F-HR VALIDATED 0001103804-05-000006
2004-09-30 2004-11-15 13F-HR VALIDATED 0001103804-04-000016
2004-06-30 2004-08-16 13F-HR VALIDATED 0001103804-04-000013
2004-03-31 2004-05-14 13F-HR QUARANTINED 0001103804-04-000008
2003-12-31 2004-02-13 13F-HR VALIDATED 0001103804-04-000004
2003-09-30 2003-11-14 13F-HR VALIDATED 0001103804-03-000034
2003-06-30 2003-08-18 13F-HR/A · restatement VALIDATED 0001103804-03-000031
2003-06-30 2003-08-18 13F-HR QUARANTINED 0001103804-03-000026
2003-03-31 2003-05-21 13F-HR/A · restatement VALIDATED 0001103804-03-000015
2003-03-31 2003-05-15 13F-HR VALIDATED 0001103804-03-000008
2002-12-31 2003-02-11 13F-HR VALIDATED 0001103804-03-000004
2001-03-31 2001-05-15 13F-HR QUARANTINED 0000728672-01-500047
2000-12-29 2001-02-13 13F-HR QUARANTINED 0000728672-01-000027
2000-09-29 2000-11-13 13F-HR QUARANTINED 0000728672-00-000186
2000-06-30 2000-08-11 13F-HR QUARANTINED 0000728672-00-000122
Open interactive changes in the app